ATE395928T1 - Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen - Google Patents

Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen

Info

Publication number
ATE395928T1
ATE395928T1 AT98966053T AT98966053T ATE395928T1 AT E395928 T1 ATE395928 T1 AT E395928T1 AT 98966053 T AT98966053 T AT 98966053T AT 98966053 T AT98966053 T AT 98966053T AT E395928 T1 ATE395928 T1 AT E395928T1
Authority
AT
Austria
Prior art keywords
growth factor
cell lines
expression vectors
vascular growth
expressing vascular
Prior art date
Application number
AT98966053T
Other languages
English (en)
Inventor
Marc Achen
Steven Stacker
Kari Alitalo
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AUPP1131A external-priority patent/AUPP113197A0/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Application granted granted Critical
Publication of ATE395928T1 publication Critical patent/ATE395928T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT98966053T 1997-12-24 1998-12-23 Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen ATE395928T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPP1131A AUPP113197A0 (en) 1997-12-24 1997-12-24 Growth factor
US8739298P 1998-05-29 1998-05-29

Publications (1)

Publication Number Publication Date
ATE395928T1 true ATE395928T1 (de) 2008-06-15

Family

ID=25645688

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98966053T ATE395928T1 (de) 1997-12-24 1998-12-23 Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen

Country Status (10)

Country Link
US (4) US7947472B2 (de)
EP (1) EP1054687B8 (de)
JP (2) JP2003517265A (de)
KR (1) KR100628697B1 (de)
CN (1) CN1345247A (de)
AT (1) ATE395928T1 (de)
CA (1) CA2315977A1 (de)
DE (1) DE69839529D1 (de)
NZ (1) NZ505011A (de)
WO (1) WO1999033485A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6824777B1 (en) 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP1283268A3 (de) 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Rekombinantes Vasculäres Endothelzellen Wachstumsfaktor D (VEGF-D)
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
CA2315977A1 (en) * 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
ATE489108T1 (de) 1998-10-09 2010-12-15 Vegenics Ltd Flt4 (vegfr-3) als ziel für tumornachweis (imaging) und antitumortherapie
WO2000037025A2 (en) 1998-12-21 2000-06-29 Ludwig Institute For Cancer Research Antibodies to truncated vegf-d and uses thereof
WO2001051075A1 (en) * 2000-01-11 2001-07-19 Epstein Stephen E Enhancing lymph channel development and treatment of lymphatic obstructive disease
AU2001239884B2 (en) * 2000-02-25 2006-08-10 Vegenics Limited Materials and methods involving hybrid vascular endothelial growth factor DNAs and proteins and screening methods for modulators
DK1259248T3 (da) * 2000-03-02 2005-04-11 Ludwig Inst Cancer Res Fremgangsmåde til behandling af cancere, der udtrykker vaskulær endotelvækstfaktor D
ATE284701T1 (de) * 2000-03-02 2005-01-15 Ludwig Inst Cancer Res Methode zur behandlung von tumoren welche den vaskulären endothelialen wachstumsfaktor d exprimieren
AU2006201128B2 (en) * 2000-03-02 2009-05-28 Vegenics Limited Methods for treating, screening for, and detecting cancers expressing vascular endothelial growth factor D
US20020102260A1 (en) * 2000-03-02 2002-08-01 Marc Achen Methods for treating neoplastic disease characterized by vascular endothelial growth factor D expression, for screening for neoplastic disease or metastatic risk, and for maintaining vascularization of tissue
AU2001264565B2 (en) * 2000-05-03 2006-12-07 Vegenics Limited A method for activating only the vascular endothelial growth factor receptor-3 and uses thereof
US20020151489A1 (en) * 2000-10-02 2002-10-17 St. Elizabeth's Medical Center Of Boston, Inc. Use of lymphangiogenic agents to treat lymphatic disorders
AU2002228841C1 (en) 2000-12-07 2006-11-23 Sangamo Biosciences, Inc Regulation of angiogenesis with zinc finger proteins
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7611711B2 (en) 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
CA2435503C (en) 2001-01-19 2011-02-22 Ludwig Institute For Cancer Research Flt4(vegfr-3) as a target for tumor imaging and anti-tumor therapy
AR027161A1 (es) * 2001-05-15 2003-03-19 Bio Sidus S A Metodo para inducir la proliferacion neovascular y regeneracion tisular
CN1555488A (zh) * 2001-07-12 2004-12-15 路德维格癌症研究院 淋巴管内皮细胞物质及方法
US20040214766A1 (en) * 2001-10-01 2004-10-28 Kari Alitalo VEGF-C or VEGF-D materials and methods for treatment of neuropathologies
US20030113324A1 (en) * 2001-10-01 2003-06-19 Kari Alitalo Neuropilin/VEGF-C/VEGFR-3 materials and methods
AUPS051002A0 (en) * 2002-02-14 2002-03-07 Riancorp Pty Ltd Low level laser therapy method and means
ITRM20020119A1 (it) * 2002-03-05 2003-09-05 Geymonat Spa Composizioni contenenti plgf ad uso farmaceutico e cosmetico.
CA2494542A1 (en) * 2002-05-03 2003-11-13 Ludwig Institute For Cancer Research Preventing secondary lymphedema with vegf-d dna
CN1327000C (zh) * 2002-09-06 2007-07-18 中国人民解放军军事医学科学院基础医学研究所 靶向黑色素瘤的可复制性腺病毒穿梭载体及腺病毒
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
US20040248796A1 (en) * 2003-02-04 2004-12-09 Kari Alitalo VEGF-B and PDGF modulation of stem cells
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
WO2005016963A2 (en) * 2003-06-12 2005-02-24 Ludwig Institute For Cancer Research Heparin binding veger-3 ligands
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
ATE553122T1 (de) 2005-02-28 2012-04-15 Sangamo Biosciences Inc Antiangiogene methoden und zusammensetzungen
EP1919944B1 (de) * 2005-08-15 2011-03-23 Vegenics Pty Ltd Modifizierte vegf und pdgf mit verbesserten angiogenen eigenschaften
US20080267924A1 (en) * 2007-02-07 2008-10-30 Vegenics Limited Autologous lymph node transfer in combination with vegf-c or vegf-d growth factor therapy to treat secondary lymphedema and to improve reconstructive surgery
WO2010065995A1 (en) * 2008-12-08 2010-06-17 Vegenics Limited Isolated vegf-c and vegf-d peptides and uses thereof
WO2012088563A1 (en) * 2010-11-24 2012-07-05 Vegenics Pty Limited Vegfr-2-specific forms of vegf-d and vegf-c and uses thereof
RS60026B1 (sr) 2013-02-18 2020-04-30 Vegenics Pty Ltd Molekuli koji vezuju ligande i njihove upotrebe

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5179426A (en) * 1987-08-04 1993-01-12 Seiko Epson Corporation Josephson device
US5179007A (en) * 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US6107046A (en) * 1992-10-09 2000-08-22 Orion Corporation Antibodies to Flt4, a receptor tyrosine kinase and uses thereof
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
EP0751992B1 (de) * 1994-03-08 2005-11-09 Human Genome Sciences, Inc. Vaskularer endothelialer wachstumsfaktor 2
DE69638142D1 (de) * 1995-09-29 2010-04-15 Univ Siena Regulierte Gene und ihre Verwendungen
US5792850A (en) * 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
WO1998002543A1 (fr) * 1996-07-15 1998-01-22 Chugai Research Institute For Molecular Medicine, Inc. Nouveaux facteurs analogues au vegf
EP1283268A3 (de) * 1996-08-23 2004-01-02 Ludwig Institute For Cancer Research Rekombinantes Vasculäres Endothelzellen Wachstumsfaktor D (VEGF-D)
AU5439998A (en) * 1996-12-06 1998-06-29 Zymogenetics Inc. Vascular endothelial growth factor
CA2315977A1 (en) 1997-12-24 1999-07-08 Ludwig Institute For Cancer Research Expression vectors and cell lines expressing vascular endothelial growth factor d, and method of treating melanomas
EP1635860A2 (de) * 2003-06-12 2006-03-22 Ludwig Institute For Cancer Research Verwendung von vegf-c oder vegf-d in der wiederherstellende chirurgie
US6889580B1 (en) * 2004-04-19 2005-05-10 A.A.G. Industrial Co., Ltd. Socket for adapting itself to open ends of wrenches of different sizes

Also Published As

Publication number Publication date
CN1345247A (zh) 2002-04-17
DE69839529D1 (de) 2008-07-03
EP1054687A4 (de) 2004-06-09
US20110269146A1 (en) 2011-11-03
JP2009159972A (ja) 2009-07-23
EP1054687B8 (de) 2008-07-16
US8461109B2 (en) 2013-06-11
JP2003517265A (ja) 2003-05-27
US7947472B2 (en) 2011-05-24
WO1999033485A1 (en) 1999-07-08
US20120270781A1 (en) 2012-10-25
KR100628697B1 (ko) 2006-09-28
CA2315977A1 (en) 1999-07-08
EP1054687B1 (de) 2008-05-21
KR20010033537A (ko) 2001-04-25
EP1054687A1 (de) 2000-11-29
US20110059890A1 (en) 2011-03-10
US20020127222A1 (en) 2002-09-12
NZ505011A (en) 2004-12-24

Similar Documents

Publication Publication Date Title
ATE395928T1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
DK1100529T3 (da) Thymosin beta 4 fremmer sårheling
DE69827001D1 (de) Gewebedezellularization
ES2114616T5 (es) Acidos dicarboxilicos alifaticos insaturados.
DE69838338D1 (de) Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
DE69010893D1 (de) Verfahren zur behandlung von koks sowie löschen desselben.
DE3578611D1 (de) Instrumente zur behandlung von verformten naegeln bei menschlichen patienten.
DE69028535D1 (de) Herstellung des vaskulären endothelialen zellwachstumsfaktors
ATE177954T1 (de) Verfahren zur behandlung von knochengeweben und implantierbare biomaterialien dafür
DE69527847D1 (de) Verwendung von anti-vegf-mitteln zur behandlung der endometriose
ATE339450T1 (de) Verfahren zur behandlung von entzündungen
EP1021179A4 (de) Verfahren zur förderung des haarwuchses und entwicklung des haarsystems
TR199801390T2 (xx) Tromboz tedavisinde kullan�lacak p�ht�la�may� �nleyici maddeler
MXPA01009415A (es) COMPOSICION DE ACIDO ASCORBICO Y METODO PARA TRATAMIENTO DE PIEL DAnADA O ENVEJECIDA.
DK0920309T3 (da) Konjugeret linolensyre til bevaring eller forøgelse af mineralindhold i knogler
EP1023005A4 (de) Verfahren zum beschichten von stents mit dna sowie zur in vivo expression von rekombinanten genen von mit dna beschichteten
ATE253934T1 (de) Verwendung eines angiogenen faktors zur behandlung von mikrovaskulären angiopathien
DE68917433D1 (de) Verfahren zur behandlung von asbest sowie asbestbehandlungsmittel.
ATE251462T1 (de) Verfahren zur behandlung von narbengewebe
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE297739T1 (de) Endothelin-antagonisten zur behandlung von herzversagen
EP0967276A3 (de) Antitumor-Mittel dass Salmosin enthält
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
EP0159446A3 (de) Kosmetische Kopfhautbehandlung
DE59100212D1 (de) Verfahren zur verformenden behandlung von keratinfasern sowie mittel zur durchfuehrung des verfahrens.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties